Overview

A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D

Status:
Completed

Trial end date:
2018-01-31

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, randomized clinical trial to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination with Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients with Chronic Hepatitis D

Phase:

Phase 2

Details

Lead Sponsor:

Hepatera Ltd.

Collaborators:

Data Matrix
Data Matrix Solutions

Treatments:

Tenofovir